PUBLISHER: GlobalData | PRODUCT CODE: 1410821
PUBLISHER: GlobalData | PRODUCT CODE: 1410821
Bordetella Pertussis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Bordetella Pertussis Tests market for the year 2020 and beyond. Bordetella pertussis, also called whooping cough, is an upper respiratory infectious disease caused by Bordetella pertussis bacteria. The disease spreads person to person by inhaling the tiny droplets of bacteria when an infected person coughs or sneezes. The B. pertussis bacteria enters the lungs, attaches to the upper part of the respiratory tract and releases toxins, which cause excessive coughing due to swelling and irritation.
Bordetella Pertussis Tests Model includes Bordetella Pertussis Nucleic Acid Amplification Tests (NAATs), Bordetella Pertussis Enzyme Immunoassays (EIAs), Multiparameter NAATs and other Bordetella pertussis tests (includes Direct Fluorescent Antibody (DFA), Culture tests and Western Blots tests, Agglutination tests, ImmunoBlot tests and Oligo-chromatographic tests) as sub-segments.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Bordetella Pertussis Test and evolving competitive landscape:
2015- 2033.
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Meridian Biosciences Inc, Hologic Inc, bioMerieux SA, DiaSorin SpA, Quidelortho Corp, Tecan Group Ltd, c, Qiagen NV, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -
Not Applicable
Not Applicable
Not Applicable